Autoimmune pancreatitis in Japan: overview and perspective
- 707 Downloads
Since the rediscovery and definition of autoimmune pancreatitis (AIP) by Yoshida et al. in 1995, the disease has been attracting attention because of its unique clinical features and practical issues. This disease shows very impressive imaging findings, serological changes, and characteristic histopathology. It occurs most commonly in elderly males with painless jaundice or mild abdominal pain; resemblance in imaging findings between AIP and pancreatobiliary cancers poses an important practical issue of differentiation. With increasing recognition of AIP and accumulation of cases, another important feature of this disease has been revealed, i.e., association of extrapancreatic organ involvements. Initially misunderstood because it can be accompanied by other autoimmune disorders, such as Sjögren’s syndrome or primary sclerosing cholangitis (PSC), AIP is now known to be associated with unique types of sialadenitis and cholangitis distinct from Sjögren’s syndrome or PSC. Now the concept of “IgG4-related sclerosing disease” has become widely accepted and the list of organs involved continues to increase. With worldwide recognition, an emerging issue is the clinical definition of other possible types of autoimmune-related pancreatitis called “idiopathic duct-centric chronic pancreatitis (IDCP)” and “AIP with granulocyte epithelial lesion (GEL)” and their relation to AIP with lymphoplasmacytic sclerosing pancreatitis (LPSP). The time has arrived to establish clinical diagnostic criteria of AIP based on international consensus and to discuss regional and racial differences in the clinicopathological features of AIP. Consensus guidelines are also required for the ideal use of steroids in the treatment of AIP to suppress recurrence efficiently with minimal side effects. There are many issues to be settled in AIP; international collaboration of experts in the pancreas field is necessary to clarify the entire picture of this unique and important disease.
KeywordsAutoimmune pancreatitis LPSP IgG4 IgG4-related sclerosing disease Steroid therapy
Autoimmune pancreatitis is a newly recognized form of pancreatic disease, recently attracting worldwide attention. More than 10 years have passed since the landmark report on the case of an AIP patient by Yoshida et al. , but the concept of AIP is not yet well-established and is, in a sense, still emerging. In this review, the current understanding of AIP is reviewed and then the issues to be settled in the near future are discussed.
Pancreatitis which develops on the basis of immunity mechanisms was first described by Sarles et al. . They reported the clinical and pathological findings of 10 patients with noncalcifying chronic pancreatitis which showed peculiar features, such as onset with obstructive jaundice, symptoms of fever, emaciation and dyspepsia, hypergammagloblinemia, and pathological findings of massive infiltration of inflammatory cells in the pancreas. After searching in vain for the causal germ, they concluded that “chronic inflammatory sclerosis of the pancreas” may be caused by a self-immunization phenomenon. It is uncertain whether the pancreatitis they reported coincides with AIP as we currently understand it, but this unique pancreatitis disappeared from the main stage of pancreatic clinical and research history for a while. Only a small number of case reports can be found before 1995  that refer to pancreatitis in accompaniment with other immune-related diseases such as Sjögren’s syndrome and PSC [3, 4, 5, 6, 7, 8]. Among them, one by Kawaguchi et al.  published in 1991 deserves special comment in that it pointed out the pancreatitis currently recognized as AIP and defined its pathological feature as lymphoplasmacytic sclerosing pancreatitis (LPSP). In 1992, the Japan Pancreas Society (JPS) launched an effort to establish the clinical criteria of chronic pancreatitis in Japan . In the process, the working committee noticed a unique pancreatitis characterized by diffuse narrowing of the main pancreatic duct (MPD) on endoscopic retrograde pancreatography (ERP) scans. The pancreatitis originally reported by Toki et al.  was described in marginal notes of the newly established JPS Criteria of Chronic Pancreatitis in 1995 as “duct-narrowing chronic pancreatitis”, a chronic inflammation of the pancreas which may not fulfill the criteria of chronic pancreatitis . This facilitated the recognition of unusual types of pancreatitis in Japan.
In 1995, Yoshida et al. reported a 68 year old female patient who developed obstructive jaundice and was diagnosed as having inoperable pancreatic cancer based on radiological findings of swollen pancreas and obstruction of the common bile duct . Only exploratory laparotomy was performed but, soon afterwards, her jaundice remitted spontaneously. The patient showed significant diffuse narrowing of MPD with an irregular wall on ERP, and elevated serum IgG and positive anti-nuclear antibody (ANA). No malignant cells and only fibrotic change with lymphocytes were observed in the needle biopsy specimen of the pancreas. Considering the possibility of pancreatitis caused by autoimmune mechanism, she was treated by oral prednisolone resulting in a resolution of pancreas swelling and normalization of the MPD and serum IgG level as well as reduction in the ANA titer. The authors designated this unusual pancreatitis as “AIP” for the first time, and defined the disease with 11 items from the common clinical and laboratory findings of 10 cases that had been reported previously [2, 3, 4, 5, 6, 7, 8].
Japanese clinical diagnostic criteria of autoimmune pancreatitis 2006
1. Diffuse or segmental narrowing of the main pancreatic duct with irregular wall and diffuse or localized enlargement of the pancreas by imaging studies, such as abdominal ultrasonography (US), computed tomography (CT), and magnetic resonance imaging (MRI)
2. High serum γ-globulin, IgG, or IgG4, or the presence of autoantibodies, such as antinuclear antibodies and rheumatoid factor
3. Marked interlobular fibrosis and prominent infiltration of lymphocytes and plasma cells in the periductal area, occasionally with lymphoid follicles in the pancreas
The spread of knowledge on AIP in the world promoted the recognition of this disease not only in Asian countries but also in Western countries [18, 19, 20, 21, 22]. Recently, an increasing number of case reports have been made from outside of Japan, confirming that this disease exists beyond regions and races. With accumulation of international information on AIP, it is becoming clear that there are different types resembling AIP [23, 24, 25]. In addition, several other diagnostic criteria of AIP were proposed from several countries such as Korea , the US  and Italy . Therefore, now is the time to seek international consensus for the clinicopathological understanding, diagnosis and treatment of AIP.
Current understanding of AIP
The RCIPD of Japan carried out a nationwide survey on AIP in 2002 .
It estimated that 900 patients fulfilled the 2002 Japanese Criteria of AIP, an incidence of 0.71/100,000 people. The number corresponds to roughly 2% of chronic pancreatitis patients in Japan whose number in 2002 was estimated to be 45,200. The same survey revealed that there were nearly 800 patients who did not satisfy the criteria; the cases were atypical but considered to be autoimmune-based pancreatitis.
Recently, Nishimori et al. reviewed the 2002 data and characterized 181 AIP patients who met the Clinical Diagnostic Criteria of AIP 2006. According to the report , the male to female ratio was 2.77, the peak age at onset was in the sixties and the patients older than 46 years old accounted for 96% of overall patients. In addition, 52% of the patients showed diffuse narrowing of the entire MPD on ERP, 38% of the patients showed segmental narrowing of MPD longer than 1/3 of the entire pancreas, while only 8% showed short segment narrowing less than 1/3 of the entire length of the MPD. It is preliminary, but the recent nationwide survey by the RCIPD of Japan predicts that the number of AIP patients in 2007 increased to 3,000, up by 1,300 compared with the 2002 survey.
There are no symptoms specific to AIP. According to the RCIPD search on the steroid responsive patients suspected of AIP , obstructive jaundice was found in 33% of patients, abdominal pain in 32%, followed by back pain in 15%, weight loss in 15%, and appetite loss and general fatigue in 9% each. It is reported that 15% of patients were asymptomatic. Abdominal pain, if any, is usually mild to moderate and severe pain such as seen in acute pancreatitis is rare. Since AIP develops frequently in elderly males with painless obstructive jaundice, mild abdominal pain or nonspecific symptoms such as weight loss and appetite loss, careful differentiation between AIP and pancreatobiliary malignant diseases is a core issue in clinical practice.
Abdominal ultrasound, endoscopic US, intraductal US
In addition to the characteristic imaging of the pancreas, US is helpful in detecting thickening of the wall of the biliary tract, the finding of sclerosing cholangitis seen in approximately 60% of AIP patients. The wall thickening is detected chiefly in the common bile duct, sometimes spreading to the gallbladder and even to the intrahepatic bile ducts . Intraductal US (IDUS) shows that the thickened wall is due to thickening of the luminal-side hypoechoic layer, while the outer hyperechoic layer is preserved .
Magnetic resonance imaging
Endoscopic retrograde cholangiopancreaticography
[18F] fluorodeoxyglucose positron emission tomography and Ga-scintigraphy
The Japanese Clinical Criteria of AIP 2006 employs serum γ-globulin (≧2.0 g/dl), IgG (≧1,800 mg/dl) and IgG4 (≧135 mg/dl) as the serum markers of AIP (Table 1) [12, 13]. The positive rates in AIP are 50–60, 60–80 and 68–92% for γ-globulin, IgG and IgG4, respectively [30, 50, 51]. Serum IgG4 is superior to IgG with a sensitivity of 86%, a specificity of 96% and accuracy of 91% in differentiation of AIP from pancreatic cancer, compared to 69, 75 and 72% for IgG .
The value of serum IgG4 as a sensitive marker of AIP was established by Hamano et al. . They reported initially that its sensitivity, specificity and accuracy for differentiating AIP from pancreatic cancer were 90.2, 97.5 and 95.0%, respectively. In addition, elevation of serum IgG4 was specific to AIP and was not seen in other diseases such as chronic pancreatitis, PSC, Sjögren’s syndrome and primary biliary cirrhosis (PBC), suggesting AIP as a distinct disease. In spite of its superiority as a marker, IgG4 is still not covered by the health insurance in Japan. As an alternative to IgG4, serum γ-globulin and IgG can be used to estimate disease activity, response to steroids and to predict recurrence . Recently Ghazale et al.  reported that 13 out of 135 pancreatic cancer patients (10%) showed slight elevation of serum IgG4 and therefore called attention to possible overconfidence in IgG4, as it is not a disease-specific marker.
Various antibodies appear in the sera of AIP patients. Representative examples include anti-lactoferrin antibody (ALF), anti-carbonic anhydrase II antibody (CA-II), ANA and Rheumatoid factor (RF) with the respective frequency of 75, 55, 60 and 20–30% . The Japanese Clinical Criteria 2006 employed ANA and RF as serum markers of AIP (Table 1). In differentiation from pancreatic cancer, the sensitivity, specificity and accuracy of ANA are 58, 79 and 67%, while those of RF are 23, 94 and 54%, respectively . Although the diagnostic capacities of these factors are not satisfactory by themselves, a combination of ANA, RF and IgG is reported to increase the sensitivity to 91%, specificity to 61% and accuracy to 78% .
SS-A (Ro) and SS-B (La) antibodies, markers of Sjögren’s syndrome, are rarely seen in AIP patients, giving additional grounds for the idea that sclerosing sialadenitis seen in AIP patients is distinct from Sjögren’s syndrome. Anti-mitochondria antibody (AMA), a specific marker of PBC, is also very rarely detected in AIP patients. It is reported that one fourth of AIP patients show a decrease in thyroid function and 34% and 17% of them are associated with positive anti-thyroglobulin antibody and anti-thyroid peroxidase (TPO) antibody, respectively .
There are some reports, chiefly from Western countries, describing AIP with unique pathological features distinct from LPSP. The pathological finding of “IDCP” or “AIP with GEL” is characterized by massive infiltration of granulocytes in the pancreatic parenchyma and into the ductal epithelium [23, 24, 25, 55, 57, 58, 60]. AIP patients with IDCP or GEL are reported to be younger, equal to both sexes, short of IgG4 abnormality, and frequently complicated with inflammatory bowel diseases. It is possible that these patients may constitute a certain group of AIP, but the current international consensus of AIP is based on the pathological findings of LPSP [13, 27, 57, 61].
Exocrine and endocrine pancreatic function
Approximately 70% of AIP patients show exocrine and endocrine dysfunction . According to the results of a 2002 nationwide survey of AIP by the RCIPD of Japan , 66.5% of 167 patients who fulfilled the Japanese Criteria of AIP 2002 had diabetes mellitus (DM). According to the report, 52% of them developed DM simultaneously at the onset of AIP, while 33% had manifested DM before the onset. Control of DM was improved by steroid therapy in 55% and 36% of these patients, respectively. Fewer than 20% of patients showed deterioration in the control of DM or development of new DM after the start of steroid treatment .
Exocrine dysfunction of AIP patients may be attributed to loss of acinar cells caused by massive infiltration of inflammatory cells and fibrosis and by disturbance of pancreatic juice flow due to periductal inflammatory cells and resulting duct narrowing. Endocrine dysfunction of AIP patients may be caused by disturbance of blood flow to islets due to parenchymal fibrosis and by impediment of islets due to spread of inflammation .
Extrapancreatic organ involvement
It has emerged that AIP cases are frequently complicated with various extrapancreatic lesions, such as swelling of lacrimal gland and sialadenitis, pulmonary hilar lymph nodes swelling , sclerosing cholangitis [66, 67], retroperitoneal fibrosis , tubulointerstitial nephritis [69, 70] and interstitial pneumonitis [71, 72]. Other lesions reported include hypophysitis , chronic thyroiditis , pseudotumor of the liver [74, 75], gastric ulcer , prostitis , Schönlein-Henoch purpura and autoimmune thrombocytopenia . It is unknown whether all of them are real complications of AIP. Representative extrapancreatic lesions have been reported as showing pathological findings similar to the pancreas, including massive lymphoplasmacytic infiltration and fibrosis, obliterating phlebitis and presence of prominent IgG4 positive plasma cells [8, 15]. AIP patients with multiple extrapancreatic lesions have higher levels of serum IgG4 than those with pancreatic involvement alone, suggesting higher activity in the former . Since AIP is characterized by elevation of serum IgG4 and appearance of numerous IgG4 positive plasma cells in various organs, Kamisawa et al. [15, 16, 17, 65] proposed the concept of “IgG4-related sclerosing disease” in which pancreatitis is a manifestation of systemic disease. Recently, some patients have been reported with periarteritis or pseudotumor of the breast or the lung, but without showing abnormal findings in the pancreas [80, 81, 82, 83]. These patients were characterized by high serum IgG4 concentrations and numerous infiltrating IgG4-positive plasma cells in the involved lesions, suggesting that IgG4-related systemic disease may occur preceding to or in the absence of pancreatitis.
Complications of AIP such as sclerosing sialadenitis, sclerosing cholangitis, pulmonary lymph node swelling, interstitial fibrosis and pseudotumors resemble Sjögren’s syndrome, PSC, sarcoidosis, idiopathic pulmonary fibrosis and malignant tumors, respectively. To confirm the diagnosis, histopathological evidence of LPSP-like findings and presence of numerous IgG4 positive plasma cells are required. Differential diagnosis can be made clinically by various serological findings and fair response to steroids in AIP. In addition, there is a tendency for sclerosing sialadenitis with AIP to involve submandibular glands symmetrically, to show infrequent dry eye symptoms, and to lack SS-A and SS-B antibodies compared with Sjögren’s syndrome. These clinical features suggest a resemblance to Mikulicz disease. Concerning sclerosing cholangitis with AIP, Nakazawa et al. [84, 85] reported that it shows some differences in the cholangiographic findings from PSC.
Autoimmune pancreatitis is unique as an autoimmune disease in its predominance in elderly males and its prompt response to steroids. So far, there is no report of familial aggregation of AIP, suggesting a multifactorial genetic disease. Kawa et al.  investigated the HLA gene and reported that the frequency of HLA DRB1*0405-DQB1*0401 haplotype was significantly higher in AIP patients than in healthy subjects and in patients with chronic calcifying pancreatitis. The relation between the HLA gene and AIP was confirmed by comprehensive mass-screening using microsatellite markers . The results suggested that presentation of some peptide antigens to T cells through HLA DRB1*0405 or HLA DQB1*0401 molecules may trigger the development of the disease.
A number of autoimmune diseases are caused by failure of peripheral immune tolerance, where regulatory T cells (CD25highCCD4+ T cells) play important suppressive roles on self-reactive T cells, to prevent the development of organ-specific autoimmune diseases. It is reported that the number of regulatory T cells increases in AIP patients and is correlated with serum IgG4 level, while the number of naïve regulatory T cells decreases .
Autoimmune pancreatitis patients in the active phase sometimes show low levels of serum complements, suggesting organ injury through complement activation. There are three pathways for activation of complements: classical, alternative and mannose binding lectin (MBL) pathways. A lack of IgG4 binding capacity to C1q, low C4 and normal MBL level in serum rules out direct relevance of IgG4 or activation of alternative and MBL pathways. In the active phase of AIP, the value of IgG4 type immune complex increases in the sera; patients who have higher values of immune complex show significantly higher IgG1, low C4 and a tendency of low C3 level . This means complement activation through IgG1-triggering classical pathway is more likely to be involved in the pathogenesis.
Uchida et al.  skillfully created a model mimicking AIP. They used a well-established mouse model of autoimmune gastritis which is created by removal of thymus at 3 days after birth. When these mice were immunized with lactoferrin (LF) or carbonic anhydrase II at the age of 6 weeks, a remarkable aggregation of lymphocytes was observed around ducts of the pancreas and salivary gland. The finding appeared again when CD4+ splenocytes of these mice were adoptively transferred to nude mice of the same strain but failed to reappear by the adoptive transfer of CD8+ splenocytes. The experiments also showed overexpression of IFN-γ in the pancreas and salivary glands of affected mice, suggesting an involvement of Th1 type immune reaction.
According to a recent survey on treatment of AIP by the RCIPD of Japan, 98% of AIP patients achieve remission by oral prednisolone (PLS) . The value is significantly higher than the patients without steroid therapy, endorsing oral PLS as the standard therapy for AIP.
Recently, the RCIPD added some items to the guidelines based on the results of an inquiry into AIP patients with jaundice in 17 high volume centers in Japan . For the initial treatment of AIP patients with jaundice, the revised guideline recommends drainage of the bile duct in cases of biliary infection. Without infection, biliary drainage is not essential but a stent-placement is recommended when ERCP is performed for diagnosis of AIP. On the other hand, from the data of time and dose of PSL at recurrence, the revised guideline recommends PSL at a dose of 5.0–7.5 mg/day for up to 3 years for maintenance therapy (Fig. 8). The study also suggested that swelling of more than 1/3 of the pancreas, uptake of Ga to extrapancreatic organs on Ga scintigraphy and sclerosing cholangitis in any part other than the lower common bile duct are risk factors of recurrence.
Issues to be settled in the future
Asian diagnostic criteria and HISORt criteria
Korean criteria for AIP
Criterion I. Imaging (both required)
Imaging (US, CT, MRI) of pancreatic parenchyma
Diffusely/segmentally/focally enlarged gland, occasionally with mass and/or hypoattenuation rim
Imaging (ERCP or MRCP) of pancreaticobiliary ducts
Diffuse/segmental/focal pancreatic ductal narrowing, often with the stenosis of bile duct
Criterion II. Serology (one required)
Elevated level of serum IgG or IgG4
Criterion III. Histopathology of pancreatic/extrapancreatic lesions (one required)
Lymphoplasmacytic infiltration and fibrosis, often with obliterative phlebitis
Presence of abundant (>10 cells/HPF) IgG4-positive plasma cells
Criterion IV. Response to steroids
Resolution/marked improvement of pancreatic/extrapancreatic lesion with steroid therapy
Diagnosis of AIP is made when any two criteria including criterion I are satisfied
Definite diagnosis (one required)
1. Criterion I together with any of criterion II to IV
Before establishing the preoperative diagnosis of AIP, thorough work-up to exclude pancreatobiliary malignancies should be performed
When it is still doubtful whether pancreatic cancer is present or not, short-interval imaging (CT and ERCP/MRCP) at 2 weeks after initiation of steroid therapy must be used to confirm whether there is resolution/marked improvement of the stricture of main pancreatic duct
2. Full spectrum of changes of lymphoplasmacytic sclerosing pancreatitis as well as abundant IgG4-positive cells infiltration on pancreatic resection specimen
Unexplained pancreatic disease without pancreatic enlargement, associated with other organ involvement or elevated serum IgG4 level
Asian diagnostic criteria for AIP
Criterion I. Imaging (both required)
1. Imaging of pancreatic parenchyma
Diffusely/segmentally/focally enlarged gland, occasionally with mass and/or hypoattenuation rim
2. Imaging of pancreaticobiliary ducts
Diffuse/segmental/focal pancreatic ductal narrowing, often with the stenosis of bile duct
Criterion II. Serology (one required)
1. Elevated level of serum IgG or IgG4
2. Detected autoantibodies
Criterion III. Histopathology of pancreatic biopsy lesion
Lymphoplasmacytic infiltration in fibrosis, common with abundant IgG4-positive plasma cell infiltration AIP should be diagnosed when criterion I and one of the other two above criteria are satisfied, or when the histology shows the presence of lymphoplasmacytic sclerosing pancreatitis in the resected pancreas
Optional criterion: response to steroid therapy
Diagnostic trials of steroid therapy could be conducted carefully by pancreatologists and only in patients fulfilling criterion I alone with negative work-up results for pancreatobiliary cancer
Diagnostic criteria for AIP (the HISORt criteria, Mayo Clinic)
At least one of the following
(1) Periductal lymphoplasmacytic infiltrate with obliterative phlebitis and storiform fibrosis (LPST)
(2) Lymphoplasmacytic infiltrate with storiform fibrosis showing abundant (≧10 cells/HPF) IgG4-positive cells
Typical: diffusely enlarged gland with delayed (rim) enhancement; diffusely irregular, attenuated main pancreatic duct
Othersa: focal pancreatic mass/enlargement; focal pancreatic duct stricture; pancreatic atrophy; pancreatic calcification; or pancreatitis
Elevated serum IgG4 level (normal 8–140 mg/dl)
Other organ involvementb
Hilar/intrahepatic biliary strictures, persistent distal biliary stricture, parotid/lacrimal gland involvement, mediastinal lymphadenopathy, retroperitoneal fibrosis
Response to steroid therapyc
Resolution/marked improvement of pancreatic/extrapancreatic manifestation with steroid therapy
LPSP and IDCP/GEL
At the AIP Summit 2008, Klöppel showed typical pathological findings of AIP with GEL [23, 24, 25]. It is reported that AIP with GEL has different clinical characteristics from AIP with LPSP, such as occurrence at younger age, lack of serum IgG4 elevation and frequent complication of inflammatory bowel diseases. Therefore, it may constitute another group of pancreatitis developing on the grounds of immunological disorders. In Japan, AIP with LPSP is predominant and only a few cases of IDCP or GEL have been known. There are two important issues. One is that there are no clinical criteria for IDCP or GEL and the definition is based solely on pathological findings. Since it is still hard to obtain large enough specimens by needle aspiration biopsy, confirmation of IDCP or GEL is clinically very difficult. The other is insufficient information regarding AIP from Western countries, especially concerning AIP with LPSP, probably due to a low recognition of this disease. This may give rise to a misunderstanding regarding the true extent of AIP in Western countries. It is important that experts of Asian and Western countries meet together and discuss regional and racial difference in the pathology and clinical features of AIP.
Consensus of steroid treatment
Consensus has not been formed concerning steroid therapy of AIP. There are two ideas. One places importance on steroid maintenance therapy after introduction of remission in order to prevent recurrence, while the other recommends early suspension of steroids but restarts oral steroids when AIP recurs. Japanese and Korean experts recommend the former and discuss the best uses of steroids for the prevention of recurrence [26, 92, 93]. Chari et al.  of the Mayo clinic recommend starting oral PSL at a dose of 40 mg/day and continuing it for 4 weeks as the initial treatment, followed by a reduction of 5 mg each week to gain remission within 11 weeks, and thereafter stopping steroid administration. The RCIPD of Japan examined 96 AIP patients who were followed up for more than 2 years after initiation of steroid therapy . The results revealed that recurrence appeared in 38 of 96 patients (39.6%), 19 in the pancreas (50%), 11 in extrapancreatic organs (29%) and 8 in both (21%). Recurrence appears within three years after the start of steroid therapy and rarely thereafter. The frequency of recurrence was significantly lower in patients treated with PSL at doses of 5.0–7.5 mg/day for maintenance compared with those maintained at doses less than 2.5 mg/day (26.5 vs. 48.1%, P = 0.045). The overall recurrence rate was 53.8% after the cessation of steroid therapy and it was seen within 1.5 years in most patients (85.7%). There are no clear data concerning which method of steroid treatment is preferrable in suppressing recurrence while holding the unfavorable side effects of steroids down, an important consideration as AIP occurrs preferentially in elderly people. A prospective randomized study is necessary to determine the best method of steroid use for treatment of AIP.
The Japanese Clinical Criteria 2006 were inadequate in diagnosing AIP in thpatients who fulfilled the imaging criteria but lacked serological findings unless histological diagnosis was confirmed. However, it is difficult to correctly diagnose of AIP on the basis of the tiny specimens obtained by US- or EUS-guided aspiration biopsy. Indeed, a recent report from Korea shows that transabdominal US-guided pancreatic core biopsy could give a correct diagnosis in only 26% of AIP patients examined . Some experts recommend the use of an EUS-guided 19-gauge Trucut needle to obtain a larger tissue sample but there are limitations for the use of such large-caliber needles due to technical difficulty and possible risk of complications . Therefore diagnostic use of steroids may be the only way to differentiate AIP with negative serum factors from pancreatic cancer. Japanese experts have been reluctant to approve diagnostic trials of steroid therapy because a certain period of steroid use might miss the best time window for surgery if the correct diagnosis were pancreatobiliary malignant disease. Kim et al. recommended reevaluation by CT and ERCP/MRCP at 2 weeks after initiation of steroid therapy to evaluate the responsiveness in the cases in whom the possibility of pancreatic cancer is not ruled out completely . Now, with agreement between Japanese and Korean experts, diagnostic trials of steroid therapy have been adopted as an optional criterion in the Asian Diagnostic Criteria for AIP . Further study is necessary to clarify the best timing and the best way to evaluate steroid response without causing unfavorable steroid effects, even if reevaluation turns out need of surgical resection for the pancreatic lesion.
Long-term prognosis of AIP is still unclear. Some reports show an appearance of pancreatic atrophy in 30–40% of AIP patients and pancreatic stones in 6.5–25% [103, 104, 105]. The appearance of stones is especially high, approximately 50% in the patients with recurrence. Kawa et al. studied 51 cases of AIP who had been followed up for more than 24 months. They reported that recurrence appeared in 41.2% and pancreatic stones in 17.6% of overall patients, 33.3% in the patients with recurrence and 6.7% in those without recurrence . This finding suggested repeating recurrence of AIP may lead to formation of pancreatic stones, as is the usual case with chronic pancreatitis.
At present there are reports of 11 AIP cases complicated with pancreatic cancer, 5 cases at the diagnosis of AIP and 6 cases at 3–5 years after initiation of steroid therapy [104, 106, 107, 108]. Iida et al.  pointed out a unique tendency for the site of occupancy: the cancer occurred in the body or tail of the pancreas in 9 of 11 cases, contrasting with dominant occurrence in the head of the pancreas generally. They called attention to a difference in the pathogenesis from ordinary ductal cancer and suggested relevance of a repeating and sustaining inflammation within the pancreas and/or immune suppression due to long-standing steroid use. Eight of 11 cases (72.7%) showed associated elevation of serum CA19-9 when cancer developed. Iida et al.  call attention to the idea that AIP may predispose to pancreatic cancer and recommend to follow up patients carefully by tumor markers and contrast-enhanced CT every 3–6 months for 2–3 years, even after the disappearance of inflammation and cessation of steroid therapy.
- 5.Semba D, Morioka Y. A case of primary sclerosing cholangitis associated with chronic pancreatitis and Sjogren syndrome. Jpn J Gastroenterol. 1987;84:2745–9.Google Scholar
- 6.Shibata T, Hayakawa T, Kondo T, Kitagawa M, Ono H, Sakai Y, et al. A case of chronic pancreatitis associated with Sjogren’s syndrome. Jpn J Gastroenterol. 1989;86:960–4.Google Scholar
- 7.Kiriyama S, Nakano S, Sugiyama K. Chronic pancreatitis associated with Sjogren’s syndrome. In: Saito Y, editor. Chronic pancreatitis in Japan. Tokyo: Kokusai-isyo-syuppan; 1991. p. 180–2.Google Scholar
- 9.Toki F, Kozu T, Oi I, Nakasako T, Suzuki M, Hanyu F. An unusual type of chronic pancreatitis showing diffuse irregular narrowing of the entire main pancreatic duct on ERCP—a report of four cases. Endoscopy. 1992;24:640.Google Scholar
- 10.The Criteria Committee for Chronic Pancreatitis of the Japan Pancreas Society. Final report of clinical diagnostic criteria of chronic pancreatitis (in Japanese). Suizo. 1995;10:xxiii–vi.Google Scholar
- 11.Members of the Criteria Committee for Autoimmune Pancreatitis of the Japan Pancreas Society. Diagnostic criteria for autoimmune pancreatitis by the Japan Pancreas Society (2002) (in Japanese with English abstract). Suizo. 2002;17:585–7.Google Scholar
- 12.Members of the Autoimmune Pancreatitis Diagnostic Criteria Committee, the Research Committee of Intractable Diseases of the Pancreas supported by the Japanese Ministry of Health, Labor and Welfare, and Members of the Autoimmune Pancreatitis Diagnostic Criteria Committee, the Japan Pancreas Society. Clinical diagnostic criteria of autoimmune pancreatitis 2006 (in Japanese with English abstract). Suizo. 2006;21:395–7.CrossRefGoogle Scholar
- 28.Nishimori I, Otsuki M. Epidemiological survey of autoimmune pancreatitis and chronic pancreatitis associating with autoimmune diseases in Japan (in Japanese). In: Fiscal 2003 annual report of surveillance study on intractable pancreatic diseases by the RCIPD Japan. 2004. p. 183–7.Google Scholar
- 30.Nishimori I, Suda K, Oi I, Ogawa M. Survey of so to call autoimmune pancreatitis—study on the clinical features of steroid-responsive cases (in Japanese). In: Fiscal 2000 annual report of surveillance study on intractable pancreatic diseases by the RCIPD Japan. 2001. p. 72–83.Google Scholar
- 34.Irie H, Honda H, Baba S, Kuroiwa T, Yoshimitsu K, Tajima T, et al. Autoimmune pancreatitis: CT and MR characteristics. Am J Roentgenol. 1998;170:1323–7.Google Scholar
- 42.Horiuchi A, Kawa S, Hamano H, Hayama M, Ota H, Kiyosawa K. ERCP features in 27 patients with autoimmune pancreatitis. Gastrointest Endosc. 2002;4:494–9.Google Scholar
- 62.Nishimori I, Suda K, Oi I, Ogawa M. The survey on the so-called autoimmune pancreatitis—comparison with pancreatic cancer and chronic pancreatitis (in Japanese). In: Fiscal 2001 annual report of surveillance study on intractable pancreatic diseases by the RCIPD Japan. 2002. p. 100–10.Google Scholar
- 63.Nishimori I, Tamakoshi A, Kawa S, Tanaka S, Takeuchi K, Kamisawa T, et al. Research Committee on Intractable Pancreatic Diseases, the Ministry of Health and Welfare of Japan. Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis. Findings from a nationwide survey in Japan. Pancreas. 2006;32:244–8.PubMedCrossRefGoogle Scholar
- 67.Nakazawa T, Ohara H, Yamada T, Ando H, Sano H, Kjino S, et al. Atypical primary sclerosing cholangitis cases associated with unusual pancreatitis. Hepatogastoroenterology. 2001;48:625–30.Google Scholar
- 91.Nishimori I, Okazaki K, Suda K, Kawa S, Kamisawa T, Tanaka S, et al. Treatment of autoimmune pancreatitis. The consensus on the treatment of autoimmune pancreatitis by The Research Committee of Intractable Diseases of the Pancreas supported by the Ministry of Health, Labor and Welfare of Japan- (in Japanese with English abstract). Suizo. 2005;20:343–8.CrossRefGoogle Scholar
- 92.Nishimori I, Okazaki K, Suda K, Kawa S, Kamisawa T, Tanaka S, et al. The consensus on the treatment of autoimmune pancreatitis—based on the survey on the actual status (in Japanese). In: Fiscal 2004 annual report of surveillance study on intractable pancreatic diseases by the RCIPD Japan. 2005. p. 223–31.Google Scholar
- 93.Nishimori I, Otsuki M. Study on the steroid treatment and recurrence of autoimmune pancreatitis (in Japanese). In: Fiscal 2005–2007 synthetic annual report of surveillance study on intractable pancreatic diseases by the RCIPD Japan. 2008. p. 190–201.Google Scholar
- 96.Kim M-H. Autoimmune pancreatitis. Gut Liver. 2007;1(Suppl 2):60–2.Google Scholar
- 100.Otsuki M, Chung JB, Okazaki K, Kim M-H, Kamisawa T, Kawa S, et al. the Research Committee of Intractable Pancreatic Diseases provided by the Ministry of Health, Labour and Welfare of Japan and the Korean Society of Pancreatobiliary Diseases. Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea symposium on autoimmune pancreatitis. J Gastroenterol. 2008;43:403–8.Google Scholar
- 109.Shimosegawa T. Diagnosis and treatment of autoimmune pancreatitis (in Japanese). Nippon Naika Gakkai Zasshi. 2007;96:146–52.Google Scholar